Literature DB >> 32756064

Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients.

Giovanna Mantovani1, Murat Bastepe2, David Monk3, Luisa de Sanctis4, Susanne Thiele5, S Faisal Ahmed6, Roberto Bufo7, Timothée Choplin8, Gianpaolo De Filippo9, Guillemette Devernois8, Thomas Eggermann10, Francesca M Elli1, Aurora Garcia Ramirez11, Emily L Germain-Lee12,13, Lionel Groussin14,15, Neveen A T Hamdy16, Patrick Hanna17, Olaf Hiort5, Harald Jüppner2, Peter Kamenický17,18,19, Nina Knight20, Elvire Le Norcy15,21, Beatriz Lecumberri22,23,24, Michael A Levine25,26, Outi Mäkitie27, Regina Martin28, Gabriel Ángel Martos-Moreno29,30,31, Manasori Minagawa32, Philip Murray33, Arrate Pereda34, Robert Pignolo35, Lars Rejnmark36, Rebeca Rodado11, Anya Rothenbuhler18,37, Vrinda Saraff38, Ashley H Shoemaker39, Eileen M Shore40, Caroline Silve41, Serap Turan42, Philip Woods20, M Carola Zillikens43, Guiomar Perez de Nanclares44, Agnès Linglart17,18,37.   

Abstract

Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by physical findings that may include brachydactyly, a short stature, a stocky build, early-onset obesity, ectopic ossifications, and neurodevelopmental deficits, as well as hormonal resistance most prominently to parathyroid hormone (PTH). In addition to these alterations, patients may develop other hormonal resistances, leading to overt or subclinical hypothyroidism, hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable evidence for hormonal abnormalities, type 2 diabetes, and skeletal issues with potentially severe limitation of mobility. PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, radiological, and biochemical presentation, establishment of the molecular diagnosis is of critical importance for patients. It facilitates management, including prevention of complications, screening and treatment of endocrine deficits, supportive measures, and appropriate genetic counselling. Based on the first international consensus statement for these disorders, this article provides an updated and ready-to-use tool to help physicians and patients outlining relevant interventions and their timing. A life-long coordinated and multidisciplinary approach is recommended, starting as far as possible in early infancy and continuing throughout adulthood with an appropriate and timely transition from pediatric to adult care.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Acrodysostosis; Bone disorders; Brachydactyly; Calcium and phosphate metabolism; Consensus; Diagnosis; Management; Ossification; Parathyroid hormone; Pseudohypoparathyroidism; Treatment

Mesh:

Year:  2020        PMID: 32756064      PMCID: PMC8140671          DOI: 10.1159/000508985

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  106 in total

1.  GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance.

Authors:  Agnès Linglart; Jean Claude Carel; Michèle Garabédian; Tran Lé; Eric Mallet; Marie Laure Kottler
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

2.  Different mutations in PDE4D associated with developmental disorders with mirror phenotypes.

Authors:  Anna Lindstrand; Giedre Grigelioniene; Daniel Nilsson; Maria Pettersson; Wolfgang Hofmeister; Britt-Marie Anderlid; Sarina G Kant; Claudia A L Ruivenkamp; Peter Gustavsson; Helena Valta; Stefan Geiberger; Alexandra Topa; Kristina Lagerstedt-Robinson; Fulya Taylan; Josephine Wincent; Tobias Laurell; Minna Pekkinen; Magnus Nordenskjöld; Outi Mäkitie; Ann Nordgren
Journal:  J Med Genet       Date:  2013-11-07       Impact factor: 6.318

3.  Cardiovascular findings in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism: A cohort study.

Authors:  Line Underbjerg; Tanja Sikjaer; Lars Rejnmark
Journal:  Clin Endocrinol (Oxf)       Date:  2019-01-27       Impact factor: 3.478

Review 4.  Nonclassic features of pseudohypoparathyroidism type 1A.

Authors:  Ashley H Shoemaker; Harald Jüppner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

5.  A GNAS1 imprinting defect in pseudohypoparathyroidism type IB.

Authors:  J Liu; D Litman; M J Rosenberg; S Yu; L G Biesecker; L S Weinstein
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients.

Authors:  Luisa de Sanctis; Sergio Vai; Maria Rita Andreo; Damiano Romagnolo; Leandra Silvestro; Carlo de Sanctis
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations.

Authors:  Francesca Marta Elli; Luisa deSanctis; Barbara Ceoloni; Anna Maria Barbieri; Paolo Bordogna; Paolo Beck-Peccoz; Anna Spada; Giovanna Mantovani
Journal:  Hum Mutat       Date:  2013-01-18       Impact factor: 4.878

8.  Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A.

Authors:  Jeffrey D Roizen; Jennifer Danzig; Veronique Groleau; Shana McCormack; Alex Casella; Jennifer Harrington; Etienne Sochett; Andrew Tershakovec; Babette S Zemel; Virginia A Stallings; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2015-12-28       Impact factor: 5.958

9.  A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.

Authors:  Susanne Thiele; Ralf Werner; Joachim Grötzinger; Bettina Brix; Pia Staedt; Dagmar Struve; Benedikt Reiz; Jennane Farida; Olaf Hiort
Journal:  Mol Genet Genomic Med       Date:  2014-12-04       Impact factor: 2.183

10.  Presentation of Hypoparathyroidism: Etiologies and Clinical Features.

Authors:  Dolores M Shoback; John P Bilezikian; Aline G Costa; David Dempster; Henning Dralle; Aliya A Khan; Munro Peacock; Marco Raffaelli; Barbara C Silva; Rajesh V Thakker; Tamara Vokes; Roger Bouillon
Journal:  J Clin Endocrinol Metab       Date:  2016-03-04       Impact factor: 5.958

View more
  9 in total

1.  Early Diagnosis of Pseudohypoparathyroidism before the Development of Hypocalcemia in a Young Infant.

Authors:  Su Kyeong Hwang; Ye Jee Shim; Seung Hwan Oh; Kyung Mi Jang
Journal:  Children (Basel)       Date:  2022-05-15

2.  Lower Leg Arterial Calcifications Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Hypoparathyroid and Pseudohypoparathyroid Patients.

Authors:  Catharina Vind Nielsen; Line Underbjerg; Diana Grove-Laugesen; Tanja Sikjaer; Lars Rejnmark
Journal:  Calcif Tissue Int       Date:  2021-02-12       Impact factor: 4.333

Review 3.  Growth Restriction and Genomic Imprinting-Overlapping Phenotypes Support the Concept of an Imprinting Network.

Authors:  Thomas Eggermann; Justin H Davies; Maithé Tauber; Erica van den Akker; Anita Hokken-Koelega; Gudmundur Johansson; Irène Netchine
Journal:  Genes (Basel)       Date:  2021-04-17       Impact factor: 4.096

4.  Calcitriol and Levothyroxine Dosing for Patients With Pseudohypoparathyroidism.

Authors:  Jacqueline Antoun; Dylan Williamson; Merla Hubler; Ashley H Shoemaker
Journal:  J Endocr Soc       Date:  2021-10-27

5.  Case Report: A Paternal 20q13.2-q13.32 Deletion Patient With Growth Retardation Improved by Growth Hormone.

Authors:  Yu Liu; Ying Yang; Liming Chu; Shuai Ren; Ying Li; Aimin Gao; Jing Wen; Wanling Deng; Yan Lu; Lingyin Kong; Bo Liang; Xiaoshan Shao
Journal:  Front Genet       Date:  2022-03-24       Impact factor: 4.599

6.  Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a.

Authors:  Masatsune Itoh; Michiko Okajima; Yuko Kittaka; Akihiro Yachie; Taizo Wada; Yutaka Saikawa
Journal:  Bone Rep       Date:  2022-04-14

7.  Characterizing Cerebral Imaging and Electroclinical Features of Five Pseudohypoparathyroidism Cases Presenting with Epileptic Seizures.

Authors:  Zijuan Qi; Zhensheng Li; Quwen Gao; Li Dong; Jian Lin; Kairun Peng; Wei Xiang; Bingmei Deng
Journal:  Behav Neurol       Date:  2022-08-12       Impact factor: 3.112

8.  Delayed diagnosis of pseudohypoparathyroidism type 1a with rare hypothyroidism since childhood.

Authors:  Ji Eun Jun; So Young Park; In-Kyung Jeong; You-Cheol Hwang; Kyu Jeong Ahn; Ho Yeon Chung
Journal:  Oxf Med Case Reports       Date:  2022-08-18

9.  High-throughput Molecular Analysis of Pseudohypoparathyroidism 1b Patients Reveals Novel Genetic and Epigenetic Defects.

Authors:  Jennifer Danzig; Dong Li; Suzanne Jan de Beur; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.